Analysts expect NeuroDerm Ltd. (NASDAQ:NDRM) to announce ($0.47) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for NeuroDerm’s earnings, with the highest EPS estimate coming in at ($0.40) and the lowest estimate coming in at ($0.51). NeuroDerm posted earnings of ($0.32) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 46.9%. The company is scheduled to issue its next earnings report on Thursday, August 24th.
According to Zacks, analysts expect that NeuroDerm will report full-year earnings of ($2.00) per share for the current financial year, with EPS estimates ranging from ($2.12) to ($1.89). For the next fiscal year, analysts expect that the company will report earnings of ($1.61) per share, with EPS estimates ranging from ($2.20) to ($0.20). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover NeuroDerm.
NeuroDerm (NASDAQ:NDRM) last posted its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.13.
Several brokerages have recently weighed in on NDRM. Raymond James Financial, Inc. downgraded shares of NeuroDerm from an “outperform” rating to a “market perform” rating and set a $39.00 price objective for the company. in a research report on Monday, July 24th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of NeuroDerm in a research report on Sunday, April 23rd. CIBC upgraded shares of NeuroDerm from a “market perform” rating to an “outperform” rating and set a $42.00 price objective for the company in a research report on Wednesday, June 14th. BidaskClub upgraded shares of NeuroDerm from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. Finally, Zacks Investment Research downgraded shares of NeuroDerm from a “hold” rating to a “sell” rating in a research report on Saturday, July 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $43.38.
NeuroDerm (NASDAQ NDRM) traded down 0.13% during mid-day trading on Tuesday, hitting $38.65. 393,674 shares of the stock were exchanged. The company has a 50 day moving average price of $30.96 and a 200 day moving average price of $26.58. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of 26.11 and a beta of 0.69. NeuroDerm has a 52-week low of $15.20 and a 52-week high of $38.85.
A number of hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC acquired a new stake in NeuroDerm during the fourth quarter valued at approximately $1,797,000. OppenheimerFunds Inc. acquired a new stake in NeuroDerm during the first quarter valued at approximately $7,588,000. Bailard Inc. increased its stake in NeuroDerm by 9.5% in the first quarter. Bailard Inc. now owns 109,000 shares of the biotechnology company’s stock valued at $2,894,000 after buying an additional 9,500 shares during the period. Bank of Montreal Can acquired a new stake in NeuroDerm during the first quarter valued at approximately $266,000. Finally, Menora Mivtachim Holdings LTD. increased its stake in NeuroDerm by 17.9% in the first quarter. Menora Mivtachim Holdings LTD. now owns 681,556 shares of the biotechnology company’s stock valued at $18,095,000 after buying an additional 103,582 shares during the period. Hedge funds and other institutional investors own 52.30% of the company’s stock.
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with our FREE daily email newsletter.